BioProcess International West

Date: 14 - 17 Mar 2016 Location: Oakland Marriott City Center City: Oakland, CA Country: USA Visit the event website for more information

We will have several presentations at this year's BioProcess International West conference.  Below are details for the presentations.  We hope to see you in Oakland.

 

Monday, March 14, 1:45 pm

 

Speaker:  Jesus Zurdo, Ph.D., Senior Director Strategic Innovation

 

Title:  "Supply-chain Integration in the Development and Manufacturing of Bioconjugate Therapeutics, A CMO Perspective" 

 

Abstract:  With a growing pipeline of molecules in development, bioconjugates are emerging as a promising therapeutic class in oncology, and other conditions, such as infectious diseases. The introduction of novel toxins, linkers, conjugations technologies or alternative architectures are modifying traditional development and manufacturing practices.  We will illustrate Lonza's efforts in integrating the inherent complexities of the bioconjugate supply-chain.





Wednesday, March 16, 10:30 am

 

Speaker:  Eytan Abraham, Ph.D., Head, Emerging Technologies R&T

 

Title:  "Modern Bioprocessing Strategies as Key Success Factor in Emerging Therapy Fields"

 

Abstract:  Increased biological understanding is enabling the development of novel and transformational therapeutics, such as cell and viral therapies.  However, the complexity of these therapies drives the need for revolutionary manufacturing methods.  Scalability, online monitoring and control over process parameters, and appropriate downstream approaches are some of the crucial manufacturing strategies that are needed to allow the commercialization of these advanced therapeutics.  These novel approaches will be demonstrated and discussed.





Thursday, March 17, 10:30 am

 

Speaker:  Jesus Zurdo, Ph.D., Senior Director Strategic Innovation

 

Title:  "Developability and Early Risk Assessment in Biopharmaceutical Development:  Towards a Holistic QbD Implementation"

 

Abstract:  Approximately 90% of drugs fail during clinical development.  This makes essential a comprehensive take on quality (big Q) that integrates manufacturing and discovery activities that are able to deliver better and more affordable therapies.  Under this acceptation of QbD, implementing developability methodologies, and computational methods in particular, can help reduce risks during early stages of development in a cost-effective way.

Bg